Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385932981> ?p ?o ?g. }
- W4385932981 abstract "The integration of immunotherapy in the perioperative setting of muscle-invasive urothelial carcinoma (MIUC) appears promising. SAKK 06/17 investigated the addition of neoadjuvant durvalumab to gemcitabine/cisplatin (GC) chemotherapy followed by radical surgery and adjuvant checkpoint inhibition with durvalumab.SAKK 06/17 was an investigator-initiated, open-label, single-arm phase II study including cisplatin-fit patients with stage cT2-T4a cN0-1 operable MIUC. Four cycles of neoadjuvant GC in combination with four cycles of durvalumab (start with GC cycle 2) were administered, followed by radical surgery. Adjuvant durvalumab was given for 10 cycles. The primary end point was event-free survival (EFS) at 2 years.Sixty one patients were accrued at 12 sites. The full analysis set consisted of 57 patients, 54 (95%) had bladder cancer. Median follow-up was 40 months. The primary end point was met, with EFS at 2 years of 76% (one-sided 90% CI [lower bound], 67%; two-sided 95% CI, 62 to 85). EFS at 3 years was 73% (95% CI, 59 to 83). Complete pathologic response in resected patients (N = 52) was achieved in 17 patients (33%), and 31 (60%) had pathologic response <ypT2 ypN0. Overall survival (OS) was 85% (95% CI, 72 to 92) at 2 years and 81% (95% CI, 67 to 89) at 3 years. Grade 3 and 4 treatment-related adverse events (TRAEs) during neoadjuvant treatment occurred in 42% and 25%, respectively. TRAEs related to adjuvant durvalumab were grade 3 in 5 (11%) and grade 4 in 2 (4%) patients.The addition of perioperative durvalumab to the standard of care for patients with resectable MIUC results in a high EFS and OS at 2 years." @default.
- W4385932981 created "2023-08-18" @default.
- W4385932981 creator A5000570624 @default.
- W4385932981 creator A5012387890 @default.
- W4385932981 creator A5013978852 @default.
- W4385932981 creator A5018539778 @default.
- W4385932981 creator A5018920707 @default.
- W4385932981 creator A5020235177 @default.
- W4385932981 creator A5038016963 @default.
- W4385932981 creator A5050931392 @default.
- W4385932981 creator A5050974067 @default.
- W4385932981 creator A5051330037 @default.
- W4385932981 creator A5058388599 @default.
- W4385932981 creator A5063978506 @default.
- W4385932981 creator A5064027207 @default.
- W4385932981 creator A5072055620 @default.
- W4385932981 creator A5077243123 @default.
- W4385932981 creator A5077298962 @default.
- W4385932981 creator A5081519723 @default.
- W4385932981 creator A5082189461 @default.
- W4385932981 creator A5083240643 @default.
- W4385932981 creator A5090904511 @default.
- W4385932981 date "2023-08-17" @default.
- W4385932981 modified "2023-10-14" @default.
- W4385932981 title "Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17" @default.
- W4385932981 cites W1845099892 @default.
- W4385932981 cites W1975918912 @default.
- W4385932981 cites W1994053739 @default.
- W4385932981 cites W2047902191 @default.
- W4385932981 cites W2071069178 @default.
- W4385932981 cites W2103561213 @default.
- W4385932981 cites W2111415894 @default.
- W4385932981 cites W2164791945 @default.
- W4385932981 cites W2166453367 @default.
- W4385932981 cites W2414977199 @default.
- W4385932981 cites W2523973428 @default.
- W4385932981 cites W2619249519 @default.
- W4385932981 cites W2745624257 @default.
- W4385932981 cites W2897581535 @default.
- W4385932981 cites W2987436342 @default.
- W4385932981 cites W3007839305 @default.
- W4385932981 cites W3023288864 @default.
- W4385932981 cites W3032403184 @default.
- W4385932981 cites W3092138236 @default.
- W4385932981 cites W3092302767 @default.
- W4385932981 cites W3135321607 @default.
- W4385932981 cites W3138703636 @default.
- W4385932981 cites W3163417926 @default.
- W4385932981 cites W3163995648 @default.
- W4385932981 cites W3168935284 @default.
- W4385932981 cites W3216663548 @default.
- W4385932981 cites W4210363402 @default.
- W4385932981 cites W4225291877 @default.
- W4385932981 cites W4225882745 @default.
- W4385932981 cites W4280556573 @default.
- W4385932981 cites W4281289322 @default.
- W4385932981 cites W4289936629 @default.
- W4385932981 cites W4300690581 @default.
- W4385932981 cites W4310059421 @default.
- W4385932981 doi "https://doi.org/10.1200/jco.23.00363" @default.
- W4385932981 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37590894" @default.
- W4385932981 hasPublicationYear "2023" @default.
- W4385932981 type Work @default.
- W4385932981 citedByCount "0" @default.
- W4385932981 crossrefType "journal-article" @default.
- W4385932981 hasAuthorship W4385932981A5000570624 @default.
- W4385932981 hasAuthorship W4385932981A5012387890 @default.
- W4385932981 hasAuthorship W4385932981A5013978852 @default.
- W4385932981 hasAuthorship W4385932981A5018539778 @default.
- W4385932981 hasAuthorship W4385932981A5018920707 @default.
- W4385932981 hasAuthorship W4385932981A5020235177 @default.
- W4385932981 hasAuthorship W4385932981A5038016963 @default.
- W4385932981 hasAuthorship W4385932981A5050931392 @default.
- W4385932981 hasAuthorship W4385932981A5050974067 @default.
- W4385932981 hasAuthorship W4385932981A5051330037 @default.
- W4385932981 hasAuthorship W4385932981A5058388599 @default.
- W4385932981 hasAuthorship W4385932981A5063978506 @default.
- W4385932981 hasAuthorship W4385932981A5064027207 @default.
- W4385932981 hasAuthorship W4385932981A5072055620 @default.
- W4385932981 hasAuthorship W4385932981A5077243123 @default.
- W4385932981 hasAuthorship W4385932981A5077298962 @default.
- W4385932981 hasAuthorship W4385932981A5081519723 @default.
- W4385932981 hasAuthorship W4385932981A5082189461 @default.
- W4385932981 hasAuthorship W4385932981A5083240643 @default.
- W4385932981 hasAuthorship W4385932981A5090904511 @default.
- W4385932981 hasConcept C121608353 @default.
- W4385932981 hasConcept C126322002 @default.
- W4385932981 hasConcept C126894567 @default.
- W4385932981 hasConcept C141071460 @default.
- W4385932981 hasConcept C143998085 @default.
- W4385932981 hasConcept C197934379 @default.
- W4385932981 hasConcept C203092338 @default.
- W4385932981 hasConcept C2776694085 @default.
- W4385932981 hasConcept C2777701055 @default.
- W4385932981 hasConcept C2777742743 @default.
- W4385932981 hasConcept C2778239845 @default.
- W4385932981 hasConcept C2778292576 @default.
- W4385932981 hasConcept C2780030458 @default.
- W4385932981 hasConcept C2780790343 @default.
- W4385932981 hasConcept C31174226 @default.